endorses problems with concentration, decreased interest in previously pleasurable activities, low energy, and racing thoughts. His girlfriend ended their relationship, reportedly due to his ongoing irritability. He was hospitalized once on a psychiatry ward at the age of 19, "because I smoked a lot of pot, didn't sleep for 3 weeks and I spent all of my parents' money on important electronics." He scores 19 out of 27 on the Patient Health Questionnaire-9.
This article is a narrative review of the diagnosis and treatment of bipolar depression in primary care. We identified articles through search strategies in PubMed, the Cochrane database, and GoogleScholar. We identified additional articles in the references of retrieved studies, and consulted with clinicians in psychiatry and primary care to develop a review that could guide clinicians in recognizing and treating bipolar depression. Much of the literature cited, particularly the studies on prevalence and co-occurring disorders, comes from the United States.
BACKGROUND AND EPIDEMIOLOGY
Bipolar I disorder is a chronic mood disorder characterized by the presence of at least one manic episode and usually recurrent major depressive episodes and often chronic depressive symptoms.
1,2 Symptoms of bipolar disorder are shown in Table 1 . Mania is the defining disease state in bipolar I disorder, and consists of a marked departure from baseline behavior and functioning, often accompanied by psychosis and/or a high risk of danger to the patient. 1 Elevated mood can occur in mania, although more commonly irritable or dysphoric mood occur, making associated symptoms such as racing thoughts, grandiosity, distractibility and impulsivity key for diagnosis. Bipolar II disorder is also a chronic disorder usually consisting of recurrent depression and at least one hypomanic episode. The symptoms and impairment of bipolar depression are similar to that of major depressive disorder, including depressed mood, feelings of worthlessness or guilt, psychomotor retardation and suicidal ideation. 3 Patients may also present with a mixed manic-depressive episode, or in a hypomanic state. Depressive symptoms contribute more to functional impairment than manic symptoms over the long-term in bipolar disorder. 4, 5 Suicidal ideation or recurrent thoughts of death can occur during all phases of bipolar illness. The lifetime prevalence of a suicide attempt is 17 % in bipolar I disorder and 24 % in bipolar II disorder, compared to 12 % in unipolar depression 6 and 0.6 % in the general US population. 7 The National Comorbidity Survey Replication estimated the lifetime prevalence of bipolar disorder in a community sample as 1.0 % for bipolar I disorder, 1.1 % for bipolar II disorder, and 2.4 % for subthreshold bipolar disorder symptoms. 8 The prevalence of bipolar disorder may be higher in primary care clinical samples, though screening instruments used in research to measure bipolar disorder prevalence, such as the Mood Disorder Questionnaire (MDQ), have limitations that are discussed below. Das et al. 9 screened 1,157 random patients from a large, urban, academic primary care clinic and found that 9.8 % (95 % CI 8.0-11.5 %) had a positive MDQ screen for a lifetime history of bipolar disorder. Three studies [10] [11] [12] using screening measures for bipolar disorder among patients already diagnosed with depression or anxiety showed a prevalence of positive screening measures for bipolar I or II disorder between 3.3 and 23.5 %. Based on a structured interview completed by a family physician, Manning et al. 13 diagnosed 18.5 % of patients with current depression or anxiety with bipolar disorder II, though only 2.8 % with bipolar I disorder.
PRESENTATION AND DIAGNOSIS
In addition to episodes of depression, mania or hypomania, patients with bipolar disorder can experience mood swings and chronic mood symptoms below the level of severity of a mood episode. Judd et al.
14 prospectively followed 146 patients with bipolar I disorder and found that patients experienced mood symptoms 47.3 % (SD 34 %) of weeks over a mean follow-up of 12.8 years, with depressive symptoms occurring three times as often as manic symptoms. Patients in this study had symptoms and impairment consistent with a full manic, hypomanic or major depressive episode 2.3 %, 4.6 % and 8.9 % of the study weeks, respectively. The same group followed 86 patients with bipolar II disorder for a mean of 13.4 years and found that patients experienced symptoms 53.9 % of the follow-up time, with depressive symptoms occurring 39 times as often as hypomanic symptoms. 15 As in bipolar I disorder, subsyndromal depressive symptoms were three times more prevalent than symptoms consistent with a full depressive episode.
Strategies to Improve Recognition in Individuals
Historical, examination and other factors can be helpful in differentiating bipolar disorder from other mood disorders. [16] [17] [18] In one primary care practice, those with a lifetime history of bipolar disorder were significantly more likely than those without bipolar disorder to have current symptoms of anorexia or overeating, low self-esteem, suicidal ideation, alcohol use, and a history of hallucinations. 12 Mitchell et al. 19, 20 systematically reviewed the literature and found that the clinical symptoms of hypersomnia, hyperphagia, leaden paralysis, psychomotor retardation, psychotic features, pathological guilt, mood lability and longer speech latency occurred more often in bipolar depression than in unipolar depression ( Table 2) .
Goldberg et al. 21 found that 31.2 % of 1,380 patients with bipolar depression experienced depression episodes without any coexisting manic symptoms. The remaining patients experienced either subsyndromal mania (1-3 manic symptoms, 54 % of patients) during the depressive episode or a (14.8 %) . Distractibility, racing thoughts and psychomotor agitation were the most commonly occurring manic symptoms. Seventyone percent of patients with bipolar II disorder and 30 % of patients with bipolar I experienced concurrent manic symptoms during the depressive episode, with male patients and those with illness onset in adolescence being more likely to have concurrent manic symptoms.
Screening and Case Identification Tools
Accurate recognition of bipolar disorder in a patient with current depressive symptoms is important, because treatment of bipolar patients with standard antidepressant medications prior to starting mood stabilizing medications can worsen their clinical outcomes. Patients with bipolar I or II disorder may present with subsyndromal symptoms such as fatigue, concentration problems, irritability, or psychomotor retardation, making a complete history of prior mood symptoms, impairment, treatment and family history vital for accurate diagnosis of bipolar disorder. Patients may also present with symptoms of a co-occurring psychiatric disorder. Among patients with any type of bipolar disorder, approximately 75 %, 42 % and 63 % have a co-occurring anxiety, substance use or impulse control disorder, respectively, 8 making questioning about bipolar disorder important in the assessment of patients with the above disorders. The diagnostic process should include obtaining a comprehensive history (including information from collateral sources and prior clinicians), and completing examinations (mental status, physical and laboratory and possibly neuropsychological testing), which may need to be spread over several clinic appointments. 18, 22 Patients with bipolar depression should be asked directly about suicidal ideation, and those with positive responses should undergo additional suicide risk assessment. 23, 24 Clinicians should seek a personal and family history of mania or hypomania, including prior treatments received, and screen for substance use disorders using evidence-based techniques, such as the AUDIT scale for alcohol use. 23 Co-occurring psychiatric disorders should also be assessed and treated. 25 Patients with bipolar disorder may receive specialty mental health care only intermittently, and as many as 10-38 % of patients receive treatment only in the primary care setting. 26 Major depression illness severity can be similar in primary care and psychiatric care settings. 27 Similarly, patients with bipolar disorder seen in primary care and specialty care can have equal degrees of functional impairment and reduced quality of life. 28, 29 Although screening tools help detect psychiatric disorders among primary care patients, screening alone, without adequate follow-up and treatment, does not improve psychiatric outcomes. 30 The diagnosis of unipolar depression in primary care has been improved by the standardization and use of tools such as the Patient Health Questionnaire-9 (PHQ-9). 31, 32 Measurement-based care with PHQ-9 has helped demonstrate that patients with depression receiving the same treatment in primary and specialty care settings had comparable treatment outcomes in a large clinical trial. 33 Several screening measures have been developed to identify patients at increased risk for bipolar disorder (see Table 2 ).
Hirschfeld et al. 34 developed the Mood Disorder Questionnaire (MDQ) as a screening instrument for bipolar disorder. In the original validation study, 34 conducted in five psychiatry clinics with a high prevalence of bipolar disorder, a score of 7 or higher on the MDQ had sensitivity of 0.73 and specificity of 0.90 for a diagnosis of bipolar disorder, when compared to the Structured Clinical Interview for DSM-IV (SCID-IV). 34 Subsequent research on the MDQ, however, has suggested that patients with positive MDQ screens were as likely to have borderline personality disorder as bipolar disorder. 35 In another study, most patients who screened positive on the MDQ 36 were found to have posttraumatic stress disorder, eating disorders and substance use disorders (based on a standardized clinical interview, SCID-IV), rather than bipolar disorder. The MDQ is a screening tool rather than a case-finding tool;, the high false positive rate requires that patients who screen positive should undergo further diagnostic assessment 37 (see example followup questions in Tables 3 and 4) .
The World Health Organization's Composite International Diagnostic Interview (CIDI) Version 3.0 is a diagnostic tool used to identify psychiatric disorders in the community, and may be a more useful tool for diagnosing bipolar disorder in primary care. 38 The CIDI Bipolar Disorder screening scale is a 3-min clinician-administered screen beginning with two stem questions. (Question 1. "Some people have periods lasting several days when they feel much more excited and full of energy than usual. Their minds go too fast. They talk a lot. They are very restless or unable to sit still and they sometimes do things that are unusual for them, such as driving too fast or spending too much money. Have you ever had a period like this lasting several days or longer?" Question 2: "Have you ever had a period lasting several days or longer when most of the time you were so irritable or grouchy that you either started arguments, shouted at people or hit people?") If the answers to the two stem questions are "no", then the CIDI is considered negative. Patients who answer "yes" to either stem question require a full CIDI assessment. The CIDI scale was concordant with the gold-standard SCID-IV (kappa 0.88 for bipolar I disorder and kappa 0.88 for bipolar II disorder or subthreshold bipolar disorder symptoms) in a national household survey, suggesting that the CIDI could be used as a casefinding measure for bipolar disorder. Clinical guidelines for the evaluation of bipolar disorder, such as the STABLE Toolkit, 23 recommend using the CIDI as the main measure for bipolar disorder case identification. The CIDI could also be used in patients scoring higher than 7 on the MDQ to confirm the likelihood of bipolar disorder diagnosis, given the low positive predictive value of the MDQ.
CO-OCCURRING DISORDERS, HEALTH RISK BEHAVIORS AND SERVICE UTILIZATION
Patients with bipolar disorder experience a 10-20 year reduction in life expectancy compared to the rest of the population, and the majority of this premature mortality is due to chronic medical illnesses. 39 Bipolar disorder is associated with sedentary behavior, obesity and tobacco use, [39] [40] [41] [42] [43] all of which are associated with an increased risk of cardiovascular disease (CVD). Approximately one-third of patients with bipolar disorder are current smokers, 44 though lifetime smoking prevalence is 44-82.5 %. 45, 46 Additionally, Simon et al. found that obesity (a body mass index (BMI) greater than 30 kg/ m 2 ) independently increased the risk of a lifetime diagnosis of bipolar disorder, (OR 1.47, 95 % CI 1.12-1.93). 47 Chwastiak et al. found a 39.2 % prevalence of obesity in patients with bipolar disorder. 48 These behaviors contribute to the development of chronic medical disorders such as obesity, type 2 diabetes and coronary heart disease at an earlier age of onset compared to primary care patients without bipolar disorder. 40, 41 Several United States studies have demonstrated higher prevalence of chronic medical conditions among patients with bipolar disorder compared to the general population. Kilbourne et al. 41 found higher prevalence of diabetes (17.2 % vs. 15.6 %, p = 0.0035), hepatitis C infection (5.9 % vs. 1.1 %, p < 0.001), lower back pain (15.4 % vs. 10.6 %, p < 0.001), chronic obstructive pulmonary disease (COPD) (10.6 % vs. 9.4 %, p=0.005), among Department of Veterans Affairs (VA) patients with bipolar disorder compared to VA patients without bipolar disorder, even though the patients with bipolar disorder were younger, on average, than patients without bipolar disorder. Higher prevalence of medical conditions among patients with bipolar disorder has also been demonstrated in non-VA samples. 49, 50 As bipolar disorder progresses, other chronic health conditions develop and accumulate 51 : patients with greater than 21 years of bipolar illness have a significantly higher burden of medical illness compared to patients with 10-20 years (p < 0.001) and 0-9 years of bipolar illness (p < 0.001), independent of patient age. Despite the high burden of general medical problems in this population, patients with bipolar disorder have significantly lower odds of having an identified primary care physician, 52 and are less likely than controls to have at least one primary care visit during a one-year study period (OR 0.63, 95 % CI 0.60-0.67). 53 In a national VA study, Kilbourne et al. 54 compared patients with bipolar disorder seen exclusively in primary care (7.6 % of patients) to those who received specialty mental health treatment. Compared to patients who received specialty care, the patients with bipolar disorder treated exclusively in primary care were more likely to have cardiovascular disease (OR=1.26, 95 % CI 1.-1-1.58, p < 0.05) or hypertension (OR=1.31, 95 % CI 1.11-1.53, p < 0.01), but were less likely to receive a mood stabilizing medication for bipolar disorder (OR=0.18, 95 % CI 0.15-0.21, p < 0.001).
Substance use disorders co-occur in as many as 42 % of outpatients with bipolar disorder, 25 and are present in approximately one-third of patients at the onset of the first mood episode. 55 Health risk behaviors, 56 chronic medical conditions 57 and substance use 58 are associated with decreased level of functioning, increased symptom burden, and lower quality of life among patients with bipolar disorder. 59 Therefore, the recognition and treatment of bipolar disorder and commonly associated health risk behaviors in primary care may lead to reduced psychiatric symptom severity, improved health and improved functioning. 26 Table 5 shows the evidence-based pharmacological treatments for bipolar depression and their associated common side effects. It is notable that only two treatments (quetiapine and olanzapine-fluoxetine combination [OFC]) have Food and Drug Administration (FDA) indications for bipolar depression.
TREATMENT PRINCIPLES

Individual Interventions
Lithium. Lithium has an FDA indication for the treatment of mania and for maintenance treatment of bipolar disorder, but not for the treatment of bipolar depression. Lithium has been shown to reduce morbidity 60 and suicide risk 61 associated with bipolar disorder. A meta-analysis 62 of long-term lithium treatment in bipolar disorder showed that lithium is effective in reducing the risk of manic relapse, and to a lesser extent, depressive relapse. Quetiapine has shown superiority over lithium in the acute treatment of bipolar depression. 63 Lithium may have a limited role as monotherapy of acute bipolar depression, though lamotrigine added to existing lithium therapy has been effective in treating bipolar depression. 64 Lithium is an important treatment in the long-term management of bipolar disorder. Thiazide diuretics, ACE inhibitors, and nonsteroidal anti-inflammatory agents increase serum lithium levels. Treatment with any of these medications requires a reduction in daily lithium dose and close laboratory monitoring.
Anticonvulsant Agents. A meta-analysis showed that divalproex 65 was more effective than placebo in producing a clinical response (risk ratio 2.1, 95 % CI 1.10-4.03) and remission (risk ratio 1.61, 95 % CI 1.02-2.53) in patients with bipolar depression. One metaanalysis of lamotrigine in bipolar depression showed that more people treated with lamotrigine experienced reduced depression symptoms compared to placebo (risk ratio 1.27, 95 % CI 1.09-1.47), and that those patients with more severe depression (measured by the Hamilton Rating Scale for Depression score > 24) had a greater benefit from lamotrigine compared to those with less severe depression. 66 However, a second meta-analysis showed that lamotrigine was not beneficial in the acute treatment of bipolar depression. 67 Antipsychotic Agents. In a meta-analysis of atypical antipsychotics in the treatment of acute bipolar depression, quetiapine (random effects estimate −5.63, 95 % CI −7.05 to −4.21) and olanzapine-fluoxetine in combination (OFC) (random effects estimate −3.10, 95 % CI −5.18 to −1.02) were superior to placebo. A systematic review of randomized, controlled treatment trials showed that OFC and quetiapine monotherapy were the most effective interventions for acute bipolar depression. 64 In newer treatment guidelines, quetiapine monotherapy has become the first-line recommendation for the treatment of bipolar depression. 68 Both olanzapine and quetiapine cause significant weight gain and dyslipidemia in many patients, and these adverse effects associated with atypical antipsychotics should be considered in treatment selection. 69 of fifteen studies showed that antidepressant medications lacked efficacy in the acute treatment of bipolar depression. However, a different metaanalysis 70 and subsequent clinical trial 71 suggest that antidepressants may have a role in the maintenance treatment of stabilized patients with bipolar disorder. In a trial without a placebo comparison, 60 patients already receiving a mood stabilizing medication who experienced a depressive episode experienced a significant reduction in depressive symptoms after receiving paroxetine or venlafaxine, although four patients in the venlafaxine group and one in the paroxetine group experienced mania or hypomania. 72 Investigators are continuing to study the role of antidepressant medications in bipolar depression. 73 The STEP-BD study was a large, federally funded multisite comparative effectiveness study of the treatment of bipolar depression. In patients with bipolar disorder treated with a mood stabilizer, there was no effect from adjunctive antidepressant treatment; only 27.3 % of patients randomized to treatment with a mood stabilizer plus placebo and 23.5 % randomized to mood stabilizer plus antidepressant (p= 0.40) recovered from the depressive episode. 74 Treatment-emergent affective switches 74 (e.g. into hypomania or mania), did not differ between treatment groups (10.1 % for the antidepressant group and 10.7 % for the placebo group, p = 0.84), though antidepressant treatment was associated with increased severity of manic symptoms at 3-month followup in patients with concurrent manic symptoms at baseline measurement during the depressive episode. 75 A systematic review 76 of anti-depressant associated mood-switching found that 13.8 % of patients with bipolar disorder exposed to antidepressant monotherapy developed elevated mood, hypomania or mania, with tricyclic antidepressants conferring the greatest risk.
There was no increase in suicidal behavior associated with antidepressant treatment of bipolar depression in the STEP-BD study. 77 In a review, McElroy et al. 78 found that patients with unrecognized bipolar disorder who received antidepressant monotherapy, but not antidepressant therapy plus a mood stabilizer, might have increased risk of experiencing suicidal ideation.
Other Treatment Principles. The BALANCE trial 79 showed that compared to valproate monotherapy, lithium monotherapy or in combination with valproate was more likely to prevent mood episode recurrence. Combination treatment (two mood stabilizing medications) may be more beneficial in preventing mood episode recurrence if the patient's most recent mood episode was treated with combination treatment. Psychosocial interventions such as social rhythm therapy and cognitive behavioral therapy are important components of treatment during depressive episodes or during the maintenance phase. In combination with appropriate pharmacotherapy, they shorten time to recovery of an acute episode, 81 shorten the time needed to achieve premorbid occupational functioning, 82 and lengthen the time until next mood episode. 83 In a randomized controlled trial 84 of stable patients with bipolar I and II disorder who were receiving appropriate pharmacotherapy, twenty one weeks of group psychoeducation was associated with lower incidence of mood episode recurrence, lower total number of mood recurrences per patient, and increased total time until next mood episode compared to a control group.
80
Population Interventions
Collaborative care models involving a population registry, treat to target guidelines, care managers, supervision by a consulting psychiatrist, brief counseling, patient self-management skills and close patient follow-up are more effective in primary care than usual care. 32, 85 No randomized controlled trials have developed health services models to test how to improve quality of care and psychiatric outcomes in patients with bipolar disorder seen in primary care. A recent metaanalysis of collaborative care models found only four trials involving patients with bipolar disorder, all of which took place in mental health care settings. 86 However, collaborative care models have improved psychiatric outcomes and slowed the decline in physical health for patients with bipolar disorder treated in psychiatric care settings. [87] [88] [89] [90] These results suggest that collaborative care for bipolar disorder may be effectively translated into the primary care setting.
SUMMARY
Patients with bipolar disorder commonly present to primary care settings. Patients experience distinct depressive, hypomanic and manic episodes, but more commonly patients have subsyndromal depressive symptoms that impair functioning. It is important to ask patients with depression about the presence of current manic symptoms, such as racing thoughts, a history of manic symptoms, hypomania or mania, substance use, family history of bipolar disorder and prior treatments. Validated case identification tools such as the CIDI can be helpful in identifying bipolar disorder in primary care patients. Evidence-based treatments for bipolar depression differ from treatments for unipolar depression. Guidelines are available from the American Psychiatric Association 91 and the STA-BLE toolkit 23 for additional information on the management of bipolar disorder. Other publications provide resources intended specifically for primary care physicians. 92 
